Answers are grounded in this paper and cite their sources.
Objectives: to evaluate the role of TP53 gene expression as a potential biomarker for multiple sclerosis. Background: Multiple sclerosis (MS) is the most prevalent non-traumatic illness among young adults. The frequency of MS and its socioeconomic effects are growing globally. Up until now, the diagnosis of MS has been considered a big challenge as it depends on a group of findings known as the McDonald criteria. However, none of those criteria is particularly specific to MS disease. This study aims to evaluate TP53 gene expression as a diagnostic marker for MS. Methods: Twenty-eight MS cases were recruited according to modified McDonald’s criteria (2017). Twenty-eight age- and sex-matched healthy subjects volunteered as a control group. Blood samples were used for RNA. The expression level of the TP53 gene was evaluated by qRT-PCR by TaqMan gene expression assay using a Rotor-Gene Q MDx 5 plex HRM instrument. Results: There was a low expression of TP53 in the MS group in comparison with the control group (P = 0.002). The ROC curve for diagnosis of MS demonstrated the best cutoff value for TP53 RQ was ≤ 0.91, with a sensitivity of 89.3% and specificity of 60.9%. There was no statistically significant correlation between disease duration in years, the expanded disability status scale (EDSS), and the annual relapse rate. Conclusion: TP53 gene expression could be a potential diagnostic biomarker for the diagnosis of MS.
No takes yet. Share an insight, caveat, or question.
Essa et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: